Over the past several years, major advances have been realized in terms of improved understanding of the pathophysiology and therapeutic options for chronic lymphocytic leukemia (CLL). The plethora of information about CLL has increased dramatically and made management of what…
Over the past several years, major advances have been realized in terms of improved understanding of the pathophysiology and therapeutic options for chronic lymphocytic leukemia (CLL). The plethora of information about CLL has increased dramatically and made management of what…
Summary of Key Points Chronic lymphocytic leukemia (CLL) is the most prevalent type of adult leukemia and is defined by a distinctive immunophenotype of CD19+, CD5+, CD23+, and surface immunoglobulin (sIg)–positive cells. The environmental or genetic cause of CLL in…
Disclosures: FTA has provided consultancy to: Genentech, Astrazeneca, Abbvie, Janssen, Pharmacyclics, Gilead sciences, Kite pharma, Celgene, Karyopharm, MEI Pharma, Verastem, Incyte, Beigene, Johnson and Johnson, Dava Oncology, BMS, Merck, Cardinal Health, ADCT therapeutics, Epizyme. PRG has provided consultancy to: Pharmacyclics…